Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
310actual
Sites
62
Countries
Australia, Canada, Germany +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-08 | actual | When the study began enrolling |
| Primary completion | 2025-11-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-21 | actual | The whole study's end, after follow-up |
| First posted | 2024-08-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity or Overweight
Interventions
- Drug: AZD5004 — also filed as Active IMP
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPercent change in body weight from baseline
measured 26 weeks
Achieved Weight Loss ≥ 5% From Baseline
measured 26 weeks
Publications
- PMID 42259337 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed